Previous close | 4.1900 |
Open | 4.2100 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 4.2100 - 4.2600 |
52-week range | 3.2010 - 4.2900 |
Volume | |
Avg. volume | 6,498 |
Market cap | 430.984M |
Beta (5Y monthly) | 0.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1200 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financial results on Thursday, May 9, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, May 9, 2024 Time: 8:30 a.m. ET Telephone: Toll Free: 1-800-836-8184 o
For many, the main point of investing is to generate higher returns than the overall market. But even the best stock...
MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com. About